Regulators In Japan Cut Away At New Drug Review Time
This article was originally published in The Pink Sheet Daily
The Japanese government is trying to eliminate the drug lag by the year 2011 under a five-year strategic plan covering the creation of innovative pharmaceuticals and medical devices.
You may also be interested in...
TOKYO - Japan is in the process of aligning itself with global pharmaceutical standards, according to Shuichi Kishida, councilor for pharmaceutical safety at the Ministry of Health, Labor and Welfare
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.